1. Scrip
  2. >>R&D
  3. >>Clinical Trials

NASH Companies Take The Stage At AASLD

AASLD Round-Up: NGM, Inventiva, Albireo Among The Companies Progressing In NASH

 
• By Joseph Haas

NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.

Liver Meeting Update, Boston 2019
Scrip checks in with a trio of mid-stage NASH companies

Without an approved therapy to establish a treatment paradigm, the non-alcoholic steatohepatitis (NASH) market is still untested – leaving the cluttered research and development space with a mix of companies testing different pathways and theories for treating the unmet medical need. At the American Association for the Study of Liver Diseases annual meeting in Boston 8-12 November, Scrip spoke to several companies with mid-stage programs about their aspirations in the crowded field.

Those companies include NGM Biopharmaceuticals Inc., which has the FGF19 analogue aldafermin (NGM282) in Phase IIb for NASH; Inventiva Pharma, which has the pan-PPAR agonist lanifibranor also in Phase IIb; and Albireo Pharma Inc., which has moved its cholestatic liver disease drug elobixibat, an IBAT inhibitor approved for chronic constipation in Japan, into NASH

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

More from R&D

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.